Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
NCT02250170
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
47
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
OPB-111077
Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Collaborators
[object Object]